Program
lebrikizumab
Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.
Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 194 open or running | phase 4since May 28, 2025 | Feb 16, 2018 | May 2027phase 3 · NCT06338995 |
| Hoffmann-La Rocheits history only | 180 open or running | phase 3since May 29, 2013 | Oct 27, 2008 | none ahead |
| Almirallits history only | 63 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | Apr 25, 2027phase 3 · NCT06526182 |
| Tanoxits history only | 10 open or running | phase 2since May 17, 2006 | May 17, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Feb 16, 2018.
- Jan 30, 20202 phase 3 studies in Dermatitis, AtopicNCT04250350, NCT04250337
- May 13, 2020Phase 3 study in Dermatitis, AtopicNCT04392154 · 1,153 enrolled · United States, Australia, Bulgaria and more
- Nov 6, 2020Phase 3 study in Dermatitis, AtopicNCT04626297 · 254 enrolled · United States
- Feb 10, 2021Phase 3 study in Dermatitis, AtopicNCT04760314 · 286 enrolled · Japan
- Apr 9, 2021Phase 1 study in HealthyNCT04840901 · 242 enrolled · United States
- May 6, 20222 phase 3 studies in Dermatitis, AtopicNCT05369403, NCT05372419
- Sep 26, 2022Phase 3 study in Dermatitis, AtopicNCT05559359 · 377 enrolled · United States, Argentina, Australia and more
- Feb 10, 2023Phase 3 study in Dermatitis, AtopicNCT05735483 · 338 planned · United States, Argentina, Australia and more
- Jan 29, 2024Phase 1 study in HealthyNCT06243198 · 24 enrolled · China
- Feb 20, 2024Phase 3 study in Dermatitis, AtopicNCT06280716 · 301 enrolled · China, South Korea
- Mar 25, 20242 phase 3 studiesNCT06339008, NCT06338995
- Apr 4, 2025Phase 3 study in Atopic Hand and Foot DermatitisNCT06921759 · 221 enrolled · United States, Argentina, Australia and more
- May 28, 2025Phase 4 study in Dermatitis, AtopicNCT07006792 · 233 enrolled · United States, Argentina, Brazil and more
- Oct 27, 2026Primary completion moved from 2026-09 to 2026-10-22Date moved laterphase 3 · +1 months · NCT06339008
Ahead
- May 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT06338995
- Dec 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT05735483
TargetBeta
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule
Other programs on IL13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| zumilokibart | AbbVie | phase 2 | 4 |
| ompekimig | Pfizer | phase 2 | 3 |
| GHZ339 | Novartis | phase 2 | 1 |
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
All 19 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07006792Dermatitis, Atopic · United States, Argentina, Brazil and more | 4 | Completed | May 14, 2026 | 233 |
| NCT06921759Atopic Hand and Foot Dermatitis · United States, Argentina, Australia and more | 3 | Completed | May 13, 2026 | 221 |
| NCT06339008Rhinitis, Allergic, Perennial · United States, Belgium, China and more | 3 | Active, not recruiting | Oct 22, 2026 | 450 |
| NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · United States, Argentina, Belgium and more | 3 | Recruiting | May 2027 | 510 |
| NCT06280716Dermatitis, Atopic · China, South Korea | 3 | Completed | Sep 25, 2025 | 301 |
| NCT06243198Healthy · China | 1 | Completed | Sep 3, 2024 | 24 |
| NCT05735483Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | By invitation | Dec 2027 | 338 |
| NCT05559359Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 14, 2026 | 377 |
| NCT05372419Dermatitis, Atopic · United States | 3 | Completed | May 3, 2024 | 90 |
| NCT05369403Dermatitis, Atopic · United States | 3 | Completed | Jan 11, 2024 | 86 |
| NCT04840901Healthy · United States | 1 | Completed | Feb 11, 2022 | 242 |
| NCT04760314Dermatitis, Atopic · Japan | 3 | Completed | Jul 31, 2022 | 286 |
| NCT04626297Dermatitis, Atopic · United States | 3 | Completed | Aug 3, 2022 | 254 |
| NCT04392154Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Jul 19, 2024 | 1,153 |
| NCT04250350Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Apr 20, 2022 | 206 |
| NCT04250337Dermatitis, Atopic · United States, Canada, Germany and more | 3 | Completed | Aug 11, 2021 | 228 |
| NCT04178967Dermatitis, Atopic · United States, Bulgaria, Canada and more | 3 | Completed | Jul 12, 2021 | 445 |
| NCT04146363Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Jun 21, 2021 | 424 |
| NCT03443024Dermatitis, Atopic · United States | 2 | Completed | Feb 7, 2019 | 280 |
How it is read
Names in the registry
- “Lebrikizumab”, 37 entries
- “lebrikizumab”, 7 entries
- “lebrikizumab (MILR1444A)”, 5 entries
- “LY3650150”, 2 entries
- “TNX-650”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 21 studies
- Asthma, 12 studies
- Nasal Polyps, 1 study
- Rhinitis, Allergic, Perennial, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.